View in EDS

Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.

Saved in:
Bibliographic Details
Title: Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
Authors: Camidge DR; Department of Medicine, University of Colorado Cancer Center, Aurora, Colorado. Electronic address: ross.camidge@cuanschutz.edu., Kim HR; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea., Ahn MJ; Division of Hematology-Oncology, Samsung Medical Center, Seoul, South Korea., Yang JCH; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan., Han JY; Department of Precision Medicine, National Cancer Center, Gyeonggi, South Korea., Hochmair MJ; Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna, Austria., Lee KH; Internal Medicine Department, Chungbuk National University Hospital, Chungbuk, South Korea., Delmonte A; Department of Medical Oncology, Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola, Italy., Garcia Campelo MR; Department of Medical Oncology, Complejo Hospitalario Universitario A Coruña (CHUAC), University Hospital A Coruña, A Coruña, Spain., Kim DW; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea., Griesinger F; Department of Hematology and Oncology, Pius-Hospital Oldenburg, University of Oldenburg, Oldenburg, Germany., Felip E; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain., Califano R; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Department of Medical Oncology, Division of Cancer Sciences, The University of Manchester, Manchester, England, United Kingdom., Spira AI; Department of Medical Oncology, Virginia Cancer Specialists, US Oncology Research, Fairfax, Virginia., Gettinger SN; Department of Medical Oncology, Yale Cancer Center, New Haven, Connecticut., Tiseo M; Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy., Lin HM; Global Evidence and Outcome, Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts., Liu Y; Oncology Statistics, Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts., Vranceanu F; Clinical Science, Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts., Niu H; Oncology Translational Sciences, Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts., Zhang P; Oncology Clinical Research, Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts., Popat S; Royal Marsden Hospital, London, United Kingdom.
Source: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2021 Dec; Vol. 16 (12), pp. 2091-2108. Date of Electronic Publication: 2021 Sep 16.
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34537440
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Camidge+DR%22">Camidge DR</searchLink>; Department of Medicine, University of Colorado Cancer Center, Aurora, Colorado. Electronic address: ross.camidge@cuanschutz.edu.<br /><searchLink fieldCode="AU" term="%22Kim+HR%22">Kim HR</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Ahn+MJ%22">Ahn MJ</searchLink>; Division of Hematology-Oncology, Samsung Medical Center, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Yang+JCH%22">Yang JCH</searchLink>; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Han+JY%22">Han JY</searchLink>; Department of Precision Medicine, National Cancer Center, Gyeonggi, South Korea.<br /><searchLink fieldCode="AU" term="%22Hochmair+MJ%22">Hochmair MJ</searchLink>; Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna, Austria.<br /><searchLink fieldCode="AU" term="%22Lee+KH%22">Lee KH</searchLink>; Internal Medicine Department, Chungbuk National University Hospital, Chungbuk, South Korea.<br /><searchLink fieldCode="AU" term="%22Delmonte+A%22">Delmonte A</searchLink>; Department of Medical Oncology, Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola, Italy.<br /><searchLink fieldCode="AU" term="%22Garcia+Campelo+MR%22">Garcia Campelo MR</searchLink>; Department of Medical Oncology, Complejo Hospitalario Universitario A Coruña (CHUAC), University Hospital A Coruña, A Coruña, Spain.<br /><searchLink fieldCode="AU" term="%22Kim+DW%22">Kim DW</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Griesinger+F%22">Griesinger F</searchLink>; Department of Hematology and Oncology, Pius-Hospital Oldenburg, University of Oldenburg, Oldenburg, Germany.<br /><searchLink fieldCode="AU" term="%22Felip+E%22">Felip E</searchLink>; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Califano+R%22">Califano R</searchLink>; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Department of Medical Oncology, Division of Cancer Sciences, The University of Manchester, Manchester, England, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Spira+AI%22">Spira AI</searchLink>; Department of Medical Oncology, Virginia Cancer Specialists, US Oncology Research, Fairfax, Virginia.<br /><searchLink fieldCode="AU" term="%22Gettinger+SN%22">Gettinger SN</searchLink>; Department of Medical Oncology, Yale Cancer Center, New Haven, Connecticut.<br /><searchLink fieldCode="AU" term="%22Tiseo+M%22">Tiseo M</searchLink>; Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy.<br /><searchLink fieldCode="AU" term="%22Lin+HM%22">Lin HM</searchLink>; Global Evidence and Outcome, Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Liu+Y%22">Liu Y</searchLink>; Oncology Statistics, Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Vranceanu+F%22">Vranceanu F</searchLink>; Clinical Science, Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Niu+H%22">Niu H</searchLink>; Oncology Translational Sciences, Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Zhang+P%22">Zhang P</searchLink>; Oncology Clinical Research, Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Popat+S%22">Popat S</searchLink>; Royal Marsden Hospital, London, United Kingdom.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101274235%22">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</searchLink> [J Thorac Oncol] 2021 Dec; Vol. 16 (12), pp. 2091-2108. <i>Date of Electronic Publication: </i>2021 Sep 16.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101274235 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1556-1380 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215560864%22">15560864 </searchLink><i>NLM ISO Abbreviation: </i>J Thorac Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34537440
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jtho.2021.07.035
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2091
    Titles:
      – TitleFull: Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Camidge DR
      – PersonEntity:
          Name:
            NameFull: Kim HR
      – PersonEntity:
          Name:
            NameFull: Ahn MJ
      – PersonEntity:
          Name:
            NameFull: Yang JCH
      – PersonEntity:
          Name:
            NameFull: Han JY
      – PersonEntity:
          Name:
            NameFull: Hochmair MJ
      – PersonEntity:
          Name:
            NameFull: Lee KH
      – PersonEntity:
          Name:
            NameFull: Delmonte A
      – PersonEntity:
          Name:
            NameFull: Garcia Campelo MR
      – PersonEntity:
          Name:
            NameFull: Kim DW
      – PersonEntity:
          Name:
            NameFull: Griesinger F
      – PersonEntity:
          Name:
            NameFull: Felip E
      – PersonEntity:
          Name:
            NameFull: Califano R
      – PersonEntity:
          Name:
            NameFull: Spira AI
      – PersonEntity:
          Name:
            NameFull: Gettinger SN
      – PersonEntity:
          Name:
            NameFull: Tiseo M
      – PersonEntity:
          Name:
            NameFull: Lin HM
      – PersonEntity:
          Name:
            NameFull: Liu Y
      – PersonEntity:
          Name:
            NameFull: Vranceanu F
      – PersonEntity:
          Name:
            NameFull: Niu H
      – PersonEntity:
          Name:
            NameFull: Zhang P
      – PersonEntity:
          Name:
            NameFull: Popat S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2021 Dec
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1556-1380
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
              Type: main
ResultId 1